The Experts below are selected from a list of 1254 Experts worldwide ranked by ideXlab platform
Y Yakuwa - One of the best experts on this subject based on the ideXlab platform.
-
VIPoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases
Journal of Experimental & Clinical Cancer Research, 1998Co-Authors: Jun Soga, Y YakuwaAbstract:Based on a statistically reliable number of cases reported in international literature, this study aimed to analyze the present status of VIPoma/diarrheogenic syndrome (DGS). Another purpose was to supply investigators in the field of pancreatic endocrinology with precise and extensive information for the future analysis and evaluation of this subject and related problems. We obtained a total of 241 patients with VIPoma/DGS from the international literature of 179 with intrapancreatic VIPomas, 48 with extrapancreatic neurogenic tumors such as ganglioneuroblastomas, ganglioneuromas and neuroblastomas, and 14 with extrapancreatic VIPomas of non-neurogenic nature. When data were considered adequate, a comparative study was attempted between the two groups. A statistically significant difference between the two groups with pancreatic VIPomas and neurogenic tumors was found in the rate of the associated syndrome (84.4% versus 95.8%: averaging 86.3%), in tumors the size of which was over 20 mm (79.1% versus 100.0%), in the metastases (56.4% versus 29.2%) and rate of malignancy (64.8% versus 33.3%), and in the rate of resection of primary lesions (68.7% versus 87.5%). When compared to nodal metastasis, hepatic involvement was significantly more frequent in the pancreatic VIPoma group (4.2% versus 20.8%). Recent trials of adjuvant chemotherapy with somatostatin analogues indicates an effective result of 78.4% exceeding 31.0% when treated with streptozotocin. The 5-year survival rate in 89 effective patients with pancreatic VIPomas was 68.5%; 59.6% for 43 of the patients with metastases and 94.4% for 46 of the patients without metastases.
-
VIPoma diarrheogenic syndrome a statistical evaluation of 241 reported cases
Journal of Experimental & Clinical Cancer Research, 1998Co-Authors: Jun Soga, Y YakuwaAbstract:Based on a statistically reliable number of cases reported in international literature, this study aimed to analyze the present status of VIPoma/diarrheogenic syndrome (DGS). Another purpose was to supply investigators in the field of pancreatic endocrinology with precise and extensive information for the future analysis and evaluation of this subject and related problems. We obtained a total of 241 patients with VIPoma/DGS from the international literature of 179 with intrapancreatic VIPomas, 48 with extrapancreatic neurogenic tumors such as ganglioneuroblastomas, ganglioneuromas and neuroblastomas, and 14 with extrapancreatic VIPomas of non-neurogenic nature. When data were considered adequate, a comparative study was attempted between the two groups. A statistically significant difference between the two groups with pancreatic VIPomas and neurogenic tumors was found in the rate of the associated syndrome (84.4% versus 95.8%: averaging 86.3%), in tumors the size of which was over 20 mm (79.1% versus 100.0%), in the metastases (56.4% versus 29.2%) and rate of malignancy (64.8% versus 33.3%), and in the rate of resection of primary lesions (68.7% versus 87.5%). When compared to nodal metastasis, hepatic involvement was significantly more frequent in the pancreatic VIPoma group (4.2% versus 20.8%). Recent trials of adjuvant chemotherapy with somatostatin analogues indicates an effective result of 78.4% exceeding 31.0% when treated with streptozotocin. The 5-year survival rate in 89 effective patients with pancreatic VIPomas was 68.5%; 59.6% for 43 of the patients with metastases and 94.4% for 46 of the patients without metastases.
Jun Soga - One of the best experts on this subject based on the ideXlab platform.
-
VIPoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases
Journal of Experimental & Clinical Cancer Research, 1998Co-Authors: Jun Soga, Y YakuwaAbstract:Based on a statistically reliable number of cases reported in international literature, this study aimed to analyze the present status of VIPoma/diarrheogenic syndrome (DGS). Another purpose was to supply investigators in the field of pancreatic endocrinology with precise and extensive information for the future analysis and evaluation of this subject and related problems. We obtained a total of 241 patients with VIPoma/DGS from the international literature of 179 with intrapancreatic VIPomas, 48 with extrapancreatic neurogenic tumors such as ganglioneuroblastomas, ganglioneuromas and neuroblastomas, and 14 with extrapancreatic VIPomas of non-neurogenic nature. When data were considered adequate, a comparative study was attempted between the two groups. A statistically significant difference between the two groups with pancreatic VIPomas and neurogenic tumors was found in the rate of the associated syndrome (84.4% versus 95.8%: averaging 86.3%), in tumors the size of which was over 20 mm (79.1% versus 100.0%), in the metastases (56.4% versus 29.2%) and rate of malignancy (64.8% versus 33.3%), and in the rate of resection of primary lesions (68.7% versus 87.5%). When compared to nodal metastasis, hepatic involvement was significantly more frequent in the pancreatic VIPoma group (4.2% versus 20.8%). Recent trials of adjuvant chemotherapy with somatostatin analogues indicates an effective result of 78.4% exceeding 31.0% when treated with streptozotocin. The 5-year survival rate in 89 effective patients with pancreatic VIPomas was 68.5%; 59.6% for 43 of the patients with metastases and 94.4% for 46 of the patients without metastases.
-
VIPoma diarrheogenic syndrome a statistical evaluation of 241 reported cases
Journal of Experimental & Clinical Cancer Research, 1998Co-Authors: Jun Soga, Y YakuwaAbstract:Based on a statistically reliable number of cases reported in international literature, this study aimed to analyze the present status of VIPoma/diarrheogenic syndrome (DGS). Another purpose was to supply investigators in the field of pancreatic endocrinology with precise and extensive information for the future analysis and evaluation of this subject and related problems. We obtained a total of 241 patients with VIPoma/DGS from the international literature of 179 with intrapancreatic VIPomas, 48 with extrapancreatic neurogenic tumors such as ganglioneuroblastomas, ganglioneuromas and neuroblastomas, and 14 with extrapancreatic VIPomas of non-neurogenic nature. When data were considered adequate, a comparative study was attempted between the two groups. A statistically significant difference between the two groups with pancreatic VIPomas and neurogenic tumors was found in the rate of the associated syndrome (84.4% versus 95.8%: averaging 86.3%), in tumors the size of which was over 20 mm (79.1% versus 100.0%), in the metastases (56.4% versus 29.2%) and rate of malignancy (64.8% versus 33.3%), and in the rate of resection of primary lesions (68.7% versus 87.5%). When compared to nodal metastasis, hepatic involvement was significantly more frequent in the pancreatic VIPoma group (4.2% versus 20.8%). Recent trials of adjuvant chemotherapy with somatostatin analogues indicates an effective result of 78.4% exceeding 31.0% when treated with streptozotocin. The 5-year survival rate in 89 effective patients with pancreatic VIPomas was 68.5%; 59.6% for 43 of the patients with metastases and 94.4% for 46 of the patients without metastases.
Tarek Amin - One of the best experts on this subject based on the ideXlab platform.
-
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male
Hematology Oncology and Stem Cell Therapy, 2014Co-Authors: Ahmed Abu-zaid, Ayman Azzam, Zainab Abudan, Amani Algouhi, Hadeel Almana, Tarek AminAbstract:VIPoma is an exceedingly unusual neuroendocrine neoplasm that autonomously secretes vasoactive intestinal polypeptide (VIP). Its reported incidence is approximately 1 per 10 million individuals per year. Herein, we report the case of sporadic pancreatic VIPoma in a 47-year-old male who presented with a six-month history of chronic, plentiful, watery diarrhea. On physical examination, the patient looked sick, lethargic and had signs of dehydration. Laboratory investigations revealed high VIP hormone level (989 pg/mL), hypokalemia, hypercalcemia, hyperglycemia, high blood urea nitrogen, high creatinine, and metabolic acidosis on arterial blood gas. Contrast-enhanced computed tomography (CT) scan showed a 3.1 · 3.3 · 4.7 cm, well-defined, enhancing lesion involving the pancreatic tail with a cystic component. Moreover, a 5.7 · 6.1 · 6.8 cm metastatic hepatic lesion was identified. The patient underwent distal pancreatectomy with splenectomy, hepatic lesion resection, and lymph node dissection. Histopathological and immunohistochemical examination of the pancreatic and hepatic lesions revealed neuroendocrine tumor (VIPoma). Postoperatively, the patient received radiofrequency ablation for the hepatic lesion. A post-operative six-month follow-up showed significant symptomatic relief, reduced VIP hormone level (71 pg/mL) and normalized electrolyte and acid–base profiles. However, a magnetic resonance imaging (MRI) scan showed a small residual metastatic liver lesion which was considered for hepatic artery embolization (HAE). The patient is still alive with a residual hepatic disease at 18 months. We also present a brief literature review on VIPoma.
-
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male
Elsevier, 2014Co-Authors: Ahmed Abu-zaid, Ayman Azzam, Zainab Abudan, Amani Algouhi, Hadeel Almana, Tarek AminAbstract:VIPoma is an exceedingly unusual neuroendocrine neoplasm that autonomously secretes vasoactive intestinal polypeptide (VIP). Its reported incidence is approximately 1 per 10 million individuals per year. Herein, we report the case of sporadic pancreatic VIPoma in a 47-year-old male who presented with a six-month history of chronic, plentiful, watery diarrhea. On physical examination, the patient looked sick, lethargic and had signs of dehydration. Laboratory investigations revealed high VIP hormone level (989 pg/mL), hypokalemia, hypercalcemia, hyperglycemia, high blood urea nitrogen, high creatinine, and metabolic acidosis on arterial blood gas. Contrast-enhanced computed tomography (CT) scan showed a 3.1 × 3.3 × 4.7 cm, well-defined, enhancing lesion involving the pancreatic tail with a cystic component. Moreover, a 5.7 × 6.1 × 6.8 cm metastatic hepatic lesion was identified. The patient underwent distal pancreatectomy with splenectomy, hepatic lesion resection, and lymph node dissection. Histopathological and immunohistochemical examination of the pancreatic and hepatic lesions revealed neuroendocrine tumor (VIPoma). Postoperatively, the patient received radiofrequency ablation for the hepatic lesion. A post-operative six-month follow-up showed significant symptomatic relief, reduced VIP hormone level (71 pg/mL) and normalized electrolyte and acid–base profiles. However, a magnetic resonance imaging (MRI) scan showed a small residual metastatic liver lesion which was considered for hepatic artery embolization (HAE). The patient is still alive with a residual hepatic disease at 18 months. We also present a brief literature review on VIPoma. Keywords: Sporadic, Pancreatic, Vasoactive intestinal polypeptide, VIPoma, Case repor
Kai Zhang - One of the best experts on this subject based on the ideXlab platform.
-
percutaneous irreversible electroporation for pancreatic VIPoma a case report
Pancreas, 2017Co-Authors: Lizhi Niu, Jianying Zeng, Gang Fang, Liang Zhou, Kai ZhangAbstract:Abstract The purpose of this study was to investigate the safety and efficacy of irreversible electroporation (IRE) for the management of unresectable pancreatic vasoactive intestinal peptide tumor (VIPoma) in a 34-year-old male patient. The initial symptom was watery diarrhea, which could not be stopped by fasting. Laboratory tests revealed high vasoactive intestinal peptide (VIP) hormone levels, hypokalemia, and metabolic acidosis. Computed tomography examination showed a 6.0 × 5.0-cm, contrast-enhanced lesion in the neck and body of the pancreas and obliteration of the portal vein. Pathological and immunohistochemical findings were indicative of pancreatic VIPoma. The patient was treated with octreotide and IRE, and had no obvious IRE-related complications, except for moderate pain at the puncture sites. The patient reported that the watery diarrhea had decreased gradually; moreover, the VIP hormone level was normalized 15 days after IRE. Computed tomography scans showed a large area of necrosis in the pancreatic lesion. The findings from this case indicated that IRE could be a feasible and safe technique in controlling pancreatic VIPoma; however, additional follow-up and findings from more cases are required to further confirm the efficacy of IRE ablation therapy for pancreatic VIPoma.
D K Meriney - One of the best experts on this subject based on the ideXlab platform.
-
pathophysiology and management of VIPoma a case study
Oncology Nursing Forum, 1996Co-Authors: D K MerineyAbstract:PURPOSE/OBJECTIVES: To review the pathophysiology and clinical treatment of VIPomas, neuroendocrine tumors that secrete vasoactive intestinal polypeptide, and VIPoma syndrome. DATA SOURCES: Published clinical treatments and case studies in the medical literature and case study data from a patient's medical record. DATA SYNTHESIS: VIPomas are rare neuroendocrine tumors that cause a syndrome of life-threatening symptoms. Clinical management is complex, yet little information is available in the medical and nursing literature to guide the clinician. CONCLUSIONS: Information about the pathophysiology and management of the disease may facilitate care of these patients. IMPLICATIONS FOR NURSING PRACTICE: A case study presentation provides an example of the care required by one patient with VIPoma. The nurse has an important role in assessing, educating, and caring for the patient with VIPoma. Interventions include managing complex fluid and electrolyte imbalances, chemotherapy administration and management of side effects, activity and rest alterations, safety issues, altered social roles, and educational needs regarding medications, central lines, and follow-up care.
